Buscopan
PreclinicalSmall molecule
Boehringer IngelheimBuscopan is one of 5 small molecule programs targeting Gastrointestinal. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Gastrointestinal
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Phase 3
Octreotide
Johnson & JohnsonPreclinical
Mosapride Citrate
IlDong Pharmaceutical Co LtdPreclinical
Buscopan
Boehringer IngelheimPreclinical
Dachengqi Decoction
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy2 trials
Gastrointestinal1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Buscopan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company